Fresenius SE & Co KGaA (FRE) Given a €76.50 Price Target at Sanford C. Bernstein

Sanford C. Bernstein set a €76.50 ($88.95) price objective on Fresenius SE & Co KGaA (FRA:FRE) in a report released on Friday. The firm currently has a buy rating on the stock.

A number of other equities research analysts have also commented on FRE. DZ Bank restated a neutral rating on shares of Fresenius SE & Co KGaA in a report on Friday. Cfra set a €45.00 ($52.33) price objective on shares of Fresenius SE & Co KGaA and gave the stock a neutral rating in a report on Friday. Independent Research set a €53.00 ($61.63) price objective on shares of Fresenius SE & Co KGaA and gave the stock a neutral rating in a report on Friday. Commerzbank set a €78.00 ($90.70) price objective on shares of Fresenius SE & Co KGaA and gave the stock a buy rating in a report on Friday. Finally, UBS Group set a €51.50 ($59.88) price objective on shares of Fresenius SE & Co KGaA and gave the stock a sell rating in a report on Friday. One analyst has rated the stock with a sell rating, eight have issued a hold rating and twelve have issued a buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average price target of €68.69 ($79.88).

Shares of FRA:FRE traded down €8.39 ($9.76) during midday trading on Friday, reaching €38.99 ($45.34). 12,548,201 shares of the company were exchanged. Fresenius SE & Co KGaA has a fifty-two week low of €60.16 ($69.95) and a fifty-two week high of €80.00 ($93.02).

Fresenius SE & Co KGaA Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Read More: What is a Derivative?

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply